Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692, 58874, 252, 304, 1980, 14717, 9941, 1941, 19310, or 17832
    6.
    发明申请
    Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692, 58874, 252, 304, 1980, 14717, 9941, 1941, 19310, or 17832 审中-公开
    使用232,2059,10630,12848,13875,14395,14618,17782,58874,252,304,1980,14717,9941,1941,199310或17832来治疗血液病症的方法和组合物

    公开(公告)号:US20060099656A1

    公开(公告)日:2006-05-11

    申请号:US11242505

    申请日:2005-10-03

    IPC分类号: G01N33/567

    摘要: The present invention relates to methods for the diagnosis and treatment of hematological disorders. Specifically, the present invention identifies the differential expression of 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692, 58874, 252, 304, 1980, 14717, 9941, 19310, or 17832 genes in tissues relating to hematological disorders sensation, relative to their expression in normal, or non-hematological disorders disease states, and/or in response to manipulations relevant to hematological disorders. The present invention describes methods for the diagnostic evaluation and prognosis of various hematological disorders, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating hematological disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of hematological disorders.

    摘要翻译: 本发明涉及诊断和治疗血液学疾病的方法。 具体地,本发明鉴定了与血液学疾病感觉有关的组织中的232,2059,10630,12848,13875,14395,14618,17712,58874,252,304,1980,14717,9941,19310或17832基因的差异表达 相对于它们在正常或非血液学疾病疾病状态中的表达,和/或响应于与血液学疾病相关的操作。 本发明描述了各种血液学疾病的诊断评价和预后的方法,以及用于鉴定表现出对这种病症倾向的受试者。 本发明还提供了鉴定能够调节血液学疾病的化合物的方法。 本发明还提供了用于鉴定和治疗化合物作为血液学疾病治疗的方法。

    RNA interference mediated inhibition of histone deacetylase (HDAC) gene expression using short interfering nucleic acid (siNA)

    公开(公告)号:US20070185049A1

    公开(公告)日:2007-08-09

    申请号:US11592039

    申请日:2006-11-02

    IPC分类号: A61K48/00 C07H21/02

    摘要: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, disease and conditions that respond to the modulation of histone deacetylase (HDAC) gene expression and/or activity. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and conditions that respond to the modulation of expression and/or activity of genes involved in HDAC gene expression pathways or other cellular processes that mediate the maintenance or development of such traits, diseases and conditions. Specifically, the invention relates to double stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating or that mediate RNA interference (RNAi) against HDAC gene expression, including cocktails of such small nucleic acid molecules and lipid nanoparticle (LNP) formulations of such small nucleic acid molecules. The present invention also relates to small nucleic acid molecules, such as siNA, siRNA, and others that can inhibit the function of endogenous RNA molecules, such as endogenous HDAC micro-RNA (miRNA) (e.g., miRNA inhibitors) or endogenous HDAC short interfering RNA (siRNA), (e.g., siRNA inhibitors) or that can inhibit the function of RISC (e.g., RISC inhibitors), to modulate HDAC gene expression by interfering with the regulatory function of such endogenous RNAs or proteins associated with such endogenous RNAs (e.g., RISC), including cocktails of such small nucleic acid molecules and lipid nanoparticle (LNP) formulations of such small nucleic acid molecules. Such small nucleic acid molecules are useful, for example, in providing compositions for treatment of traits, diseases and conditions that can respond to modulation of HDAC gene expression in a subject or organism, such as cancer and other proliferative diseases or conditions that are associated with HDAC gene expression or activity.

    Methods and compositions for treating hematological disorders using 9118, 990, 17662, 81982, 630, 21472, 17692, 19290, 21620, 21689, 28899, 53659, 64549, 9465, 23544, 7366, 27417, 57259, 21844, 943, 2061, 5891, 9137, 13908, 14310, 17600, 25584, 27824, 28469, 38947, 53003, 965, 56639, 9661, 16052, 1521, 6662, 13913, 12405 or 5014
    9.
    发明申请
    Methods and compositions for treating hematological disorders using 9118, 990, 17662, 81982, 630, 21472, 17692, 19290, 21620, 21689, 28899, 53659, 64549, 9465, 23544, 7366, 27417, 57259, 21844, 943, 2061, 5891, 9137, 13908, 14310, 17600, 25584, 27824, 28469, 38947, 53003, 965, 56639, 9661, 16052, 1521, 6662, 13913, 12405 or 5014 审中-公开
    使用9118,990,17662,81982,630,2172,27892,19290,21620,21689,28899,53659,64549,9465,23544,7366,27417,57259,21844,943,2061的治疗血液病症的方法和组合物, 5891,9137,13908,14310,17600,25584,27824,28469,38947,53003,965,56639,961,61652,1521,6662,13913,12405或5014

    公开(公告)号:US20060078947A1

    公开(公告)日:2006-04-13

    申请号:US11288493

    申请日:2005-11-29

    IPC分类号: G01N33/567 G01N33/53

    CPC分类号: C07K14/47 A61K38/00

    摘要: The present invention relates to methods for the diagnosis and treatment of hematological disorders. Specifically, the present invention identifies the differential expression of 9118, 990, 17662, 81982, 630, 21472, 17692, 19290, 21620, 21689, 28899, 53659, 64549, 9465, 23544, 7366, 27417, 57259, 21844, 943, 2061, 5891, 9137, 13908, 14310, 17600, 25584, 27824, 28469, 38947, 53003, 965, 56639, 9661, 16052, 1521, 6662, 13913, 12405 and 5014 genes in tissues relating to hematological disorders sensation, relative to their expression in normal, or non-hematological disorders disease states, and/or in response to manipulations relevant to hematological disorders. The present invention describes methods for the diagnostic evaluation and prognosis of various hematological disorders, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating hematological disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of hematological disorders.

    摘要翻译: 本发明涉及诊断和治疗血液学疾病的方法。 具体而言,本发明鉴定了9118,990,17662,81982,630,2172,27892,19290,21620,21689,28899,53659,64549,9465,23544,7366,27417,57259,21844,943的差异表达, 2061,5981,9137,13908,14310,1769,25584,27824,28469,38947,53003,965,5666,99661,16052,1521,6662,13913,12405和5014与血液学疾病感觉有关的组织中的基因,相对于 它们在正常或非血液学疾病疾病状态中的表达,和/或响应于与血液学疾病相关的操作。 本发明描述了各种血液学疾病的诊断评价和预后的方法,以及用于鉴定表现出对这种病症倾向的受试者。 本发明还提供了鉴定能够调节血液学疾病的化合物的方法。 本发明还提供了用于鉴定和治疗化合物作为血液学疾病治疗的方法。

    Deployable electromagnetic concentrator

    公开(公告)号:US20060044213A1

    公开(公告)日:2006-03-02

    申请号:US10929070

    申请日:2004-08-27

    IPC分类号: H01Q15/20

    CPC分类号: H01Q1/288

    摘要: A deployable electromagnetic concentrator comprises a facet stem hub assembly having at least one rotatable segment and a plurality of facets stems coupled thereto. At least one of the facet stems is coupled to at least one of the rotatable segments. The concentrator further comprises a plurality of facet stems, each being coupled to a different one of the rotatable segments for rotating the plurality of facets from a substantially overlapping configuration to a substantially non-overlapping configuration.